Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 9
Encontrada(s) 1 página(s)

Repositori Obert UdL
Publicación Artículo científico (JournalArticle)

Industrial By-Products As a Novel Circular Source of Biocompatible Extracellular Vesicles

  • Lorca, Cristina
  • Laparra, Moisés
  • Céspedes, María Virtudes
  • Casaní, Laura
  • Florit, Sergi
  • Jové Font, Mariona
  • Mota Martorell, Natàlia
  • Vilella, Elisabet
  • Gallart Palau, Xavier Ramon
  • Serra, Aida
Extracellular vesicles (EVs) constitute an intricate system of molecular exchange that has recently gained tremendous interest. However, sustainable sources of safe biological EVs remain scarce and elusive. This study explores and defines the use of food industry by-products (BP) as a circular source of safe biocompatible EVs. Averaged diameter and molecular compositions indicate a large yield of exosomes and high abundancy of membrane lipids with signaling capacity in these vesicles. Complex proteomes mimicking those circulating in human blood plasma are also identified. Furthermore, BP-EVs do not show relevant cytotoxicity and display excellent oral and intravenous bioavailability together with specific organ targeting capacity. Collectively, it is believed that the novel findings reported here will open substantial venues for the use of BP as an optimal source of biocompatible nanovesicles in manifold applications of the biotechnological and biomedical fields., The authors sincerely thank Gemma Plaza, oenologist at the Castell del Remei winery in Penelles, Lleida, Spain and Juan Carlos Blanco, production manager at Mahou San Miguel in Alovera, Madrid, Spain for their kind and altruistic help on the obtention of their respective industry by-product samples. The authors also thank Dr. Hector Peinado and his research group at the National Center for Oncology Research (CNIO) in Madrid (Spain) for their support on the morphometric characterization of BP-EVs. Support for this work was provided by the Research and Education Council of the Community of Madrid, Spain (2018-T1/ BIO-10633), Ministry of Science and Innovation, Spain (PID2020- 114885RB-C21) and a FIS project by Carlos III Institute of Health (ISCIII), Spain (PI20/00623). A.S. acknowledges a grant from the Talento Program 2018 of the Community of Madrid. X.G.-P. acknowledges grants from Sara Borrell postdoctoral program (CD19/00243) and Miguel Servet tenure track program (CP21/00096) of the Instituto de Salud Carlos III (ISCIII, Spain), respectively awarded on the 2019 and 2021 calls under ISCIII-Health Strategy Actions [These grants are cofunded with European Union Funds (ISCIII Miguel Servet Program 2021 is cofunded by Fondo Social Europeo Plus, FSE+)]. M.V.C. acknowledges a Miguel Servet program contract (CPII20/00007). C.L.’s Ph.D. was funded by the Regional Ministry of Science, Universities and Innovation of the Community of Madrid and the European Social Fund for the recruitment of predoctoral researchers (PEJD-2019-PRE/BIO-16475). IRBLLEIDA and X.G.-P. are co-funded by CERCA Program/Generalitat de Catalunya.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Industrial By-Products As a Novel Circular Source of Biocompatible Extracellular Vesicles

  • Lorca, Cristina
  • Laparra, Moisés
  • Céspedes, María Virtudes
  • Casaní, Laura
  • Florit, Sergi
  • Jové Font, Mariona
  • Mota Martorell, Natàlia
  • Vilella, Elisabet
  • Gallart Palau, Xavier Ramon
  • Serra, Aida
Extracellular vesicles (EVs) constitute an intricate system of molecular exchange that has recently gained tremendous interest. However, sustainable sources of safe biological EVs remain scarce and elusive. This study explores and defines the use of food industry by-products (BP) as a circular source of safe biocompatible EVs. Averaged diameter and molecular compositions indicate a large yield of exosomes and high abundancy of membrane lipids with signaling capacity in these vesicles. Complex proteomes mimicking those circulating in human blood plasma are also identified. Furthermore, BP-EVs do not show relevant cytotoxicity and display excellent oral and intravenous bioavailability together with specific organ targeting capacity. Collectively, it is believed that the novel findings reported here will open substantial venues for the use of BP as an optimal source of biocompatible nanovesicles in manifold applications of the biotechnological and biomedical fields., The authors sincerely thank Gemma Plaza, oenologist at the Castell del Remei winery in Penelles, Lleida, Spain and Juan Carlos Blanco, production manager at Mahou San Miguel in Alovera, Madrid, Spain for their kind and altruistic help on the obtention of their respective industry by-product samples. The authors also thank Dr. Hector Peinado and his research group at the National Center for Oncology Research (CNIO) in Madrid (Spain) for their support on the morphometric characterization of BP-EVs. Support for this work was provided by the Research and Education Council of the Community of Madrid, Spain (2018-T1/ BIO-10633), Ministry of Science and Innovation, Spain (PID2020- 114885RB-C21) and a FIS project by Carlos III Institute of Health (ISCIII), Spain (PI20/00623). A.S. acknowledges a grant from the Talento Program 2018 of the Community of Madrid. X.G.-P. acknowledges grants from Sara Borrell postdoctoral program (CD19/00243) and Miguel Servet tenure track program (CP21/00096) of the Instituto de Salud Carlos III (ISCIII, Spain), respectively awarded on the 2019 and 2021 calls under ISCIII-Health Strategy Actions [These grants are cofunded with European Union Funds (ISCIII Miguel Servet Program 2021 is cofunded by Fondo Social Europeo Plus, FSE+)]. M.V.C. acknowledges a Miguel Servet program contract (CPII20/00007). C.L.’s Ph.D. was funded by the Regional Ministry of Science, Universities and Innovation of the Community of Madrid and the European Social Fund for the recruitment of predoctoral researchers (PEJD-2019-PRE/BIO-16475). IRBLLEIDA and X.G.-P. are co-funded by CERCA Program/Generalitat de Catalunya.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

All-in-one biofabrication and loading of recombinant vaults in human cells

  • Martín, Fernando|||0000-0002-3496-9093
  • Carreño, Aida|||0000-0001-7725-7515
  • Mendoza Moreno, Rosa|||0000-0002-0488-4814
  • Caruana Santiago, Pablo|||0000-0002-0170-4355
  • Rodríguez, Francisco|||0000-0001-7909-932X
  • Bravo, Marlon|||0000-0002-0065-9812
  • Benito, Antoni|||0000-0002-9776-1003
  • Ferrer-Miralles, Neus|||0000-0003-2981-3913
  • Céspedes, María Virtudes|||0000-0003-2956-5833
  • Corchero Nieto, José Luis|||0000-0002-6109-144X
One of the most promising approaches in the drug delivery field is the use of naturally occurring self-assembling protein nanoparticles, such as virus-like particles, bacterial microcompartments or vault ribonucleoprotein particles as drug delivery systems (DDSs). Among them, eukaryotic vaults show a promising future due to their structural features, in vitro stability and non-immunogenicity. Recombinant vaults are routinely produced in insect cells and purified through several ultracentrifugations, both tedious and time-consuming processes. As an alternative, this work proposes a new approach and protocols for the production of recombinant vaults in human cells by transient gene expression of a His-tagged version of the major vault protein (MVP-H6), the development of new affinity-based purification processes for such recombinant vaults, and the all-in-one biofabrication and encapsulation of a cargo recombinant protein within such vaults by their co-expression in human cells. Protocols proposed here allow the easy and straightforward biofabrication and purification of engineered vaults loaded with virtually any INT-tagged cargo protein, in very short times, paving the way to faster and easier engineering and production of better and more efficient DDS.
Dipòsit Digital de Documents de la UAB
Publicación Artículo de revisión (ReviewArticle)

Nano-based approved pharmaceuticals for cancer treatment, present and future challenges

  • Rodríguez, Francisco|||0000-0001-7909-932X
  • Caruana Santiago, Pablo|||0000-0002-0170-4355
  • De la Fuente, Noa
  • Español, Pia|||0000-0002-1164-6355
  • Gámez, Maria
  • Balart, Josep|||0000-0002-1173-7556
  • Llurba, Elisa|||0000-0003-4048-6407
  • Rovira Negre, Ramon|||0000-0003-4136-4153
  • Ruiz, Raúl
  • Martín-Lorente, Cristina|||0000-0002-9827-0521
  • Corchero Nieto, José Luis|||0000-0002-6109-144X
  • Céspedes, María Virtudes|||0000-0003-2956-5833
Cancer is one of the main causes of death worldwide. To date, and despite the advances in conventional treatment options, therapy in cancer is still far from optimal due to the non-specific systemic biodistribution of antitumor agents. The inadequate drug concentrations at the tumor site led to an increased incidence of multiple drug resistance and the appearance of many severe unde-sirable side effects. Nanotechnology, through the development of nanoscale-based pharmaceuticals, has emerged to provide new and innovative drugs to overcome these limitations. In this review, we provide an overview of the approved nanomedicine for cancer treatment and the rationale behind their designs and applications. We also highlight the new approaches that are currently under investigation and the perspectives and challenges for nanopharmaceuticals, focusing on the tumor microenvironment and tumor disseminate cells as the most attractive and effective strategies for cancer treatments.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Escherichia coli as a New Platform for the Fast Production of Vault-like Nanoparticles, An Optimized Protocol

  • Fernández, Roger
  • Carreño, Aida|||0000-0001-7725-7515
  • Mendoza Moreno, Rosa|||0000-0002-0488-4814
  • Benito, Antoni|||0000-0002-9776-1003
  • Ferrer-Miralles, Neus|||0000-0003-2981-3913
  • Céspedes, María Virtudes|||0000-0003-2956-5833
  • Corchero Nieto, José Luis|||0000-0002-6109-144X
Vaults are protein nanoparticles that are found in almost all eukaryotic cells but are absent in prokaryotic ones. Due to their properties (nanometric size, biodegradability, biocompatibility, and lack of immunogenicity), vaults show enormous potential as a bio-inspired, self-assembled drug-delivery system (DDS). Vault architecture is directed by self-assembly of the "major vault protein" (MVP), the main component of this nanoparticle. Recombinant expression (in different eukaryotic systems) of the MVP resulted in the formation of nanoparticles that were indistinguishable from native vaults. Nowadays, recombinant vaults for different applications are routinely produced in insect cells and purified by successive ultracentrifugations, which are both tedious and time-consuming strategies. To offer cost-efficient and faster protocols for nanoparticle production, we propose the production of vault-like nanoparticles in Escherichia coli cells, which are still one of the most widely used prokaryotic cell factories for recombinant protein production. The strategy proposed allowed for the spontaneous encapsulation of the engineered cargo protein within the self-assembled vault-like nanoparticles by simply mixing the clarified lysates of the producing cells. Combined with well-established affinity chromatography purification methods, our approach contains faster, cost-efficient procedures for biofabrication in a well-known microbial cell factory and the purification of "ready-to-use" loaded protein nanoparticles, thereby opening the way to faster and easier engineering and production of vault-based DDSs.
Dipòsit Digital de Documents de la UAB
Publicación Artículo de revisión (ReviewArticle)

Neural plasticity of the uterus, New targets for endometrial cancer?

  • Español, Pia|||0000-0002-1164-6355
  • Luna-Guibourg, Rocío|||0000-0003-4861-8339
  • Soler, Cristina
  • Caruana Santiago, Pablo|||0000-0002-0170-4355
  • Altés-Arranz, Amanda
  • Rodríguez-Lozano, Francisco|||0000-0002-1503-0750
  • Porta, Oriol|||0000-0001-6000-9566
  • Sánchez García, Olga|||0000-0002-5279-440X
  • Llurba, Elisa|||0000-0003-4048-6407
  • Rovira Negre, Ramon|||0000-0003-4136-4153
  • Céspedes, María Virtudes|||0000-0003-2956-5833
Endometrial carcinoma is the most common gynecological malignancy in Western countries and is expected to increase in the following years because of the high index of obesity in the population. Recently, neural signaling has been recognized as part of the tumor microenvironment, playing an active role in tumor progression and invasion of different solid tumor types. The uterus stands out for the physiological plasticity of its peripheral nerves due to cyclic remodeling brought on by estrogen and progesterone hormones throughout the reproductive cycle. Therefore, a precise understanding of nerve-cancer crosstalk and the contribution of the organ-intrinsic neuroplasticity, mediated by estrogen and progesterone, of the uterine is urgently needed. The development of new and innovative medicines for patients with endometrial cancer would increase their quality of life and health. This review compiles information on the architecture and function of autonomous uterine neural innervations and the influence of hormone-dependent nerves in normal uterus and tumor progression. It also explores new therapeutic possibilities for endometrial cancer using these endocrine and neural advantages.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Industrial By-Products As a Novel Circular Source of Biocompatible Extracellular Vesicles

  • Lorca, Cristina
  • Laparra, Moisés
  • Céspedes, María Virtudes|||0000-0003-2956-5833
  • Casaní, Laura|||0000-0002-0139-4588
  • Florit, Sergi
  • Jové, Mariona|||0000-0001-5577-6162
  • Mota-Martorell, Natàlia|||0000-0001-5937-7070
  • Vilella, Elisabet|||0000-0002-1887-5919
  • Gallart-Palau, Xavier
  • Serra, Aida
Extracellular vesicles (EVs) constitute an intricate system of molecular exchange that has recently gained tremendous interest. However, sustainable sources of safe biological EVs remain scarce and elusive. This study explores and defines the use of food industry by-products (BP) as a circular source of safe biocompatible EVs. Averaged diameter and molecular compositions indicate a large yield of exosomes and high abundancy of membrane lipids with signaling capacity in these vesicles. Complex proteomes mimicking those circulating in human blood plasma are also identified. Furthermore, BP-EVs do not show relevant cytotoxicity and display excellent oral and intravenous bioavailability together with specific organ targeting capacity. Collectively, it is believed that the novel findings reported here will open substantial venues for the use of BP as an optimal source of biocompatible nanovesicles in manifold applications of the biotechnological and biomedical fields.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Tuning plasmid DNA amounts for cost-effective transfections of mammalian cells, when less is more

  • Carreño, Aida|||0000-0001-7725-7515
  • Guerrero-Yagüe, Rubén|||0000-0002-6012-2734
  • Casal, Enriqueta|||0000-0002-0334-0380
  • Mendoza, Rosa|||0000-0002-0488-4814
  • Corchero Nieto, José Luis|||0000-0002-6109-144X
Transient gene expression (TGE) in mammalian cells is a well-known approach to the fast expression of recombinant proteins. The human cell line HEK (human embryonic kidney) 293F is widely used in this field, due to its adaptability to grow in suspension to high cell densities in serum-free media, amenability to transfection, and production of recombinant proteins in satisfactory quantities for functional and structural analysis. Amounts of plasmid DNA (pDNA) required in transfections for TGE remain high (usually 1 µg pDNA/mL, or even higher), representing a noticeable proportion of the overall cost. Thus, there is an economic need to reduce amounts of coding pDNA in TGE processes. In this work, amounts of both pDNA and transfecting agent used for TGE in HEK 293F cells have been explored in order to reduce them without compromising (or even improving) the productivity of the process in terms of protein yield. In our hands, minimal polyethyleneimine (PEI) cytotoxicity and optimum protein yields were obtained when transfecting at 0.5 µg pDNA/mL (equal to 0.5 µg pDNA/million cells) and a DNA-to-PEI ratio of 1:3, a trend confirmed for several unrelated recombinant proteins. Thus, carefully tuning pDNA and transfecting agent amounts not only reduces the economic costs but also results in higher recombinant protein yields. These results surely have a direct application and interest for the biopharmaceutical industry, always concerned in increasing productivity while decreasing economic costs. • Mammalian cells are widely used to produce recombinant proteins in short times. • Tuning DNA and transfecting agent are of great interest to optimize economic costs. • Reducing DNA and transfecting agent amounts result in higher protein yields.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Dopamine receptors D1 and D2 show prognostic significance and potential therapeutic applications for endometrial cancer patients

  • Español, Pia|||0000-0002-1164-6355
  • Rovira Negre, Ramon|||0000-0003-4136-4153
  • Caruana Santiago, Pablo|||0000-0002-0170-4355
  • Luna-Guibourg, Rocío|||0000-0003-4861-8339
  • Soler, Cristina
  • Teixeira, Natalia|||0000-0002-6457-6215
  • Rodríguez, Francisco|||0000-0001-7909-932X
  • Gallardo, Alberto|||0000-0002-2514-2027
  • Edwards, Maria
  • Porta, Oriol|||0000-0001-6000-9566
  • Gámez, Maria
  • Sánchez Martínez, M. Olga|||0000-0003-1254-012X
  • Llurba, Elisa|||0000-0003-4048-6407
  • Corchero Nieto, José Luis|||0000-0002-6109-144X
  • Céspedes, María Virtudes|||0000-0003-2956-5833
Catecholaminergic signaling has been a target for therapy in different type of cancers. In this work, we characterized the ADRβ2, DRD1 and DRD2 expression in healthy tissue and endometrial tumors to evaluate their prognostic significance in endometrial cancer (EC), unraveling their possible application as an antitumor therapy. 109 EC patients were included. The expression of the ADRβ2, DRD1 and DRD2 proteins was evaluated by immunohistochemistry and univariate and multivariate analysis to assess their association with clinic-pathological and outcome variables. Finally, HEC1A and AN3CA EC cell lines were exposed to different concentrations of selective dopaminergic agents alone or in combination to study their effects on cellular viability. ADRβ2 protein expression was not associated with clinico-pathological parameters or prognosis. DRD1 protein expression was reduced in tumors samples but showed a significant inverse association with tumor size and stage. DRD2 protein expression was significantly associated with non-endometrioid EC, high grade tumors, tumor size, worse disease-free survival (HR = 3.47 (95%CI:1.35-8.88)) and overall survival (HR = 2.98 (95%CI:1.40-6.34)). The DRD1 agonist fenoldopam showed a reduction of cellular viability in HEC1A and AN3CA cells. The exposure to domperidone, a DRD2 antagonist, significantly reduced cell viability compared to the control. Finally, DRD1 agonism and DRD2 antagonism combination induced a significant reduction in cell viability of the AN3CA cells compared to monotherapy, close to being an additive response than a synergistic effect (CI of 1.1 at 0.5% Fa). DRD1 and DRD2 expression levels showed a significant association with clinico-pathological parameters. Both the combined activation of DRD1 and blockage of DRD2 may form an innovative strategy to inhibit tumor growth in EC.